Physician profile
Daniel Benasher
NPI 1780927558
$801.73
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $148 · 2021: $321 · 2022: $158 · 2023: $33.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $125.00 | 2022 | |
| Janssen Biotech, INC. | $111.37 | 2019-2020 | |
| Kite Pharma, INC. | $88.07 | 2021 | |
| Global Blood Therapeutics, INC. | $79.92 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $79.72 | 2019-2021 | |
| Astellas Pharma US INC | $50.22 | 2021-2022 | |
| Lilly USA, LLC | $45.39 | 2019-2021 | |
| Tactile Systems Technology INC | $33.20 | 2023 | Entre Plus, Flexitouch Plus |
| Puma Biotechnology, INC. | $30.00 | 2019 | |
| Tesaro, INC. | $28.00 | 2019 | |
| Rigel Pharmaceuticals, INC. | $25.99 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.89 | 2019 | |
| Servier Pharmaceuticals LLC | $16.64 | 2021 | |
| Innate Pharma, INC | $16.18 | 2020 | |
| Exelixis INC. | $13.94 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.50 | 2020 | |
| Kyowa Kirin, INC. | $13.13 | 2021 | |
| Dova Pharmaceuticals | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Benasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.